Oren Gilad insider trades: Aprea Therapeutics (APRE) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Oren reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | APRE | ↑ Buy | 28,100 | $0.89 | $25K | Direct | Feb 2, 2026 (3d) |
| Apr 3, 2025 | APRE | ↑ Buy | 5,500 | $1.84 | $10K | Direct | Apr 4, 2025 (1d) |
| Oct 23, 2024 | APRE | ↑ Buy | 500 | $3.92 | $2K | Direct | Oct 24, 2024 (1d) |
| Oct 15, 2024 | APRE | ↑ Buy | 250 | $2.90 | $725 | Direct | Oct 16, 2024 (1d) |
| Oct 14, 2024 | APRE | ↑ Buy | 1,150 | $2.58 | $3K | Direct | Oct 15, 2024 (1d) |
| Mar 13, 2024 | APRE | ↑ Buy | 2,000 | $7.29 | $15K | Direct | Mar 14, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APRE insiders
Open-market trades in the last 12 months
About Oren Gilad's insider trades
Oren Gilad is President/CEO at Aprea Therapeutics (APRE). Since Mar 13, 2024, Oren has reported 6 open-market purchases worth $55K and no sales on SEC Form 4. In the last 12 months: 1 buy ($25K).
Their filings also include grants and awards (5 filings), other transactions (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.